These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 19820124)

  • 1. PPARgamma agonists, modulation of ion transporters, and fluid retention.
    Nofziger C; Blazer-Yost BL
    J Am Soc Nephrol; 2009 Dec; 20(12):2481-3. PubMed ID: 19820124
    [No Abstract]   [Full Text] [Related]  

  • 2. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
    Guan Y; Hao C; Cha DR; Rao R; Lu W; Kohan DE; Magnuson MA; Redha R; Zhang Y; Breyer MD
    Nat Med; 2005 Aug; 11(8):861-6. PubMed ID: 16007095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluid retention mediated by renal PPARgamma.
    Staels B
    Cell Metab; 2005 Aug; 2(2):77-8. PubMed ID: 16098822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Releasing the pressure.
    Davenport RJ
    Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf47. PubMed ID: 15975897
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.
    Zhou L; Liu G; Jia Z; Yang KT; Sun Y; Kakizoe Y; Liu M; Zhou S; Chen R; Yang B; Yang T
    Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1491-7. PubMed ID: 24005472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.
    Mao Z; Ong AC
    Nephron Clin Pract; 2009; 112(4):c230-41. PubMed ID: 19546582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TZDs and diabetes: testing the waters.
    Semenkovich CF
    Nat Med; 2005 Aug; 11(8):822-4. PubMed ID: 16079871
    [No Abstract]   [Full Text] [Related]  

  • 9. PPARgamma agonists: safety issues in heart failure.
    Tang WH; Maroo A
    Diabetes Obes Metab; 2007 Jul; 9(4):447-54. PubMed ID: 17587386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung turns to AA (adenosine analogues) to dry out.
    Kreindler JL; Shapiro SD
    Nat Med; 2007 Apr; 13(4):406-8. PubMed ID: 17415371
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
    Liu W; Liu K; Wood HB; McCann ME; Doebber TW; Chang CH; Akiyama TE; Einstein M; Berger JP; Meinke PT
    J Med Chem; 2009 Jul; 52(14):4443-53. PubMed ID: 19530681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium transporters in kidney role in health and disease.
    Sahay M; Narayen G; Anuradha
    J Assoc Physicians India; 2007 Feb; 55():135-9. PubMed ID: 17571744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.
    Connors RV; Wang Z; Harrison M; Zhang A; Wanska M; Hiscock S; Fox B; Dore M; Labelle M; Sudom A; Johnstone S; Liu J; Walker NP; Chai A; Siegler K; Li Y; Coward P
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3550-4. PubMed ID: 19464171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly functionalized 7-azaindoles as selective PPAR gamma modulators.
    Debenham SD; Chan A; Lau FW; Liu W; Wood HB; Lemme K; Colwell L; Habulihaz B; Akiyama TE; Einstein M; Doebber TW; Sharma N; Wang CF; Wu M; Berger JP; Meinke PT
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4798-801. PubMed ID: 18701276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective, potent PPARgamma agonists with cyclopentenone core structure.
    Otero MP; Pérez Santín E; Rodríguez-Barrios F; Vaz B; de Lera AR
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1883-6. PubMed ID: 19275963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NASH and thiazolidinediones: not to be taken lightly.
    Dufour JF
    J Hepatol; 2007 Oct; 47(4):451-3. PubMed ID: 17692990
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of water and ion transporters in tracheal aspirates from neonates with respiratory distress.
    Li Y; Marcoux MO; Gineste M; Vanpee M; Zelenina M; Casper C
    Acta Paediatr; 2009 Nov; 98(11):1729-37. PubMed ID: 19719801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator activator receptor gamma (PPARgamma) agonists as therapeutic adjuncts in critical illness: efficacy might be suboptimal in elderly patients.
    Fink MP
    Crit Care Med; 2009 Jun; 37(6):2123-5. PubMed ID: 19448468
    [No Abstract]   [Full Text] [Related]  

  • 19. Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo.
    Kumar AP; Quake AL; Chang MK; Zhou T; Lim KS; Singh R; Hewitt RE; Salto-Tellez M; Pervaiz S; Clément MV
    Cancer Res; 2009 Nov; 69(22):8636-44. PubMed ID: 19887620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung liquid transport components in human perinatal respiratory distress.
    Pitkänen OM
    Acta Paediatr; 2009 Nov; 98(11):1709-11. PubMed ID: 19807703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.